New Big Cover Segnaposto

Project IMPACT

Lutech Group will be part of the team that will study the development of new therapies for arrhythmogenic cardiomyopathy using Artificial Intelligence


Patients and their data at the centre of digital transformation

healthcare Discover you road map

The research project, named IMPACT - Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment - will run for 36 months and has been funded with 4 million euros by the European Innovation Council for cardiogenomics. The mission of the European Innovation Council (EIC), established by the European Commission in 2021, is to identify and to develop innovative technologies for research.

The international team, led by Professor Alessandra Rampazzo of the Department of Biology at the University of Padua and composed of researchers from Universiteit Maastricht (Dr. Martina Calore), Universitair Medisch Centrum Utrecht (Dr. Anneline te Riele), Lutech Group (Dr. Barbara Alicino), Italbiotec Consortium (Dr. Melissa Balzarotti), Ksilink (Dr. Peter Sommer), and Italfarmaco (Dr. Christian Steinkuhler), will study the development of new therapies for arrhythmogenic cardiomyopathy (ACM), a genetic disease that affects the heart and represents one of the main causes of ventricular arrhythmias and sudden cardiac death. With an incidence of 1 in 5000, it can be considered a highly relevant cardiovascular disease.

Arrhythmogenic cardiomyopathy is a degenerative heart condition often implicated in the sudden death of athletes and adolescents. The histopathological hallmark is fibroadipose replacement of the myocardium, which impairs the functioning of the cardiac muscle, leading to the onset of ventricular arrhythmias. Currently, there is no therapy available to prevent or at least slow down the progressive tissue changes that could be ultimately fatal.

Mutations in numerous disease genes have been identified as contributors to this condition. However, many of the genetic alterations found in the DNA of affected patients have uncertain significance and are not yet directly linked to the disease, providing limited utility for both geneticists and physicians.

«Thanks to the funding obtained from Horizon Europe, our research project aims to open up new therapeutic perspectives based on the results obtained from various disease models. This is an innovative and multidisciplinary project, whose success is strongly supported by the diverse but complementary expertise of partners from academic institutions and leading companies in the fields of computer science, biotechnology, and pharmaceuticals," says Professor Alessandra Rampazzo of the Department of Biology at the University of Padua and scientific coordinator of the international team. "Such collaboration will allow us to achieve our ambitious goals. The overall objective of the project funded by the European Community is to integrate and analyze clinical and molecular data from the ACM patient registry using artificial intelligence, along with data from structural and functional analyses of cellular models such as three-dimensional cardiac microtissues and in vivo models. These results will enable us to gain a better understanding of the role and impact of genetic alterations on the clinical progression of arrhythmogenic cardiomyopathy. Additionally," Alessandra Rampazzo concludes, "the project includes screening and subsequent evaluation of the therapeutic potential of several compounds and innovative molecules, both in cellular and animal models.»

«We are proud to be part of this ambitious research project about arrhythmogenic cardiomyopathy research project," says Franco Prampolini, Head of Advanced Industry Solutions at Lutech Group. At Lutech, we believe that the key to making significant progress in understanding and treating this serious cardiovascular disease is collaboration between partners with complementary skills. We are grateful to Horizon Europe for supporting this initiative, which will enable us to provide digital expertise and solutions for analyzing and understanding clinical data also through the use of artificial intelligence.»

The discovery of new therapeutic targets and an understanding of the underlying molecular mechanisms could not only lead to new therapies for ACM but could also pave the way for better clinical management of the disease and an improvement in the quality of life for patients.

The meeting of all participants, which will officially launch the project, will be held in Padua on October 26th and 27th.

Download the press release

Contact Lutech

We invite you to read the marketing policy disclaimer.

Please enter a value
Please enter a value
Please enter a valid email address
Please enter a valid phone number
Please enter a value
Please enter a value
Please enter a value

By clicking the "Confirm" button, I declare that I have read and understood the Marketing Disclaimer

I agree to receive commercial and promotional communications relating to services and products as well as information messages relating to marketing activities, as explained in the aforementioned Disclaimer

Please select an option

An error has occurred, please try again later

Thank you for your interest!
We have received your contact request; we will be in touch shortly to further discuss your business requirements.


Lutech end to end solutions